Patents

US 11980689 B2: Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH)

Granted
2024-05-14
Filed
2020-09-22 application 17028630
Type
Utility · 12 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Disclosed herein are formulations of imatinib or a phenylaminopyrimidine derivative compound for aerosolization and use of such formulations for inhaled aerosol administration of imatinib or a phenylaminopyrimidine derivative compound for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. In some embodiments, formulations and delivery options described herein allow for efficacious local delivery of imatinib or a phenylaminopyrimidine derivative compound or salt thereof. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that may benefit by reformulation and inhalation administration.

Source: PVGPATDIS, file of 2026-04-10 (ipg240514.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
AVALYN PHARMA INC. 13 patentsUS company or organizationSeattle, WAAvalyn Pharma Inc. State business registration EXACT high confidence: identical full name and state
Avalyn Pharma Inc. Form D issuer EXACT high confidence: identical full name and state
AVALYN PHARMA INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Mark William SurberSan Diego, CA31PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K9/14PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P11/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2020-09-22Name change
Change of name
WINDWARD PHARMA, INC. signed 2017-07-26AVALYN PHARMA INC. SEATTLE, WA53852/947PASDL, file of 2026-10-15
2020-09-22Assignment
Assignment of assignor's interest
SURBER, MARK WILLIAM signed 2014-08-13WINDWARD PHARMA, INC. SAN DIEGO, CA53848/761PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.